Skip to main content
. 2017 Jan 4;8(7):11206–11218. doi: 10.18632/oncotarget.14493

Figure 7. Combination of Rad001 and ATO can significantly inhibit the growth of prostate cancer LNCaP cells xenograft in a mouse model.

Figure 7

(A) Anti-tumor activity on LNCaP xenografts by various compounds. Mice were administered daily i.p. with Rad001 at 1 mg/kg, ATO at 2 mg/kg, and both daily (6 mice/group). The tumor sizes were measured every four days. (*P < 0.05 compared with untreated animals. **P < 0.05 compared with RAD001-treated animals or ATO-treated animals). (B) The mice weights were measured every four days (*P > 0.05 compared with untreated animals. **P > 0.05 compared with RAD001-treated animals or ATO-treated animals). (C) Tumors treated with two compounds were much smaller than single compound treatment or control. The LNCaP xenograft tumors were dissected after 44 days. (D) Immunoblot analysis for LC3 and Beclin1 from the lysate prepared from the xenograft.